Intec Pharma Ltd. (NTEC) Reaches $5.18 After 7.00% Down Move; Fort Washington Investment Advisors Has Increased Unilever N V (UN) Stake

April 16, 2018 - By Pete Kolinski

Unilever N.V. (NYSE:UN) Logo

The stock of Intec Pharma Ltd. (NASDAQ:NTEC) is a huge mover today! The stock decreased 1.43% or $0.07 during the last trading session, reaching $5.18. About 141,189 shares traded. Intec Pharma Ltd. (NASDAQ:NTEC) has risen 25.00% since April 16, 2017 and is uptrending. It has outperformed by 13.45% the S&P500.The move comes after 6 months negative chart setup for the $173.83M company. It was reported on Apr, 16 by Barchart.com. We have $4.82 PT which if reached, will make NASDAQ:NTEC worth $12.17M less.

Fort Washington Investment Advisors Inc increased Unilever N V (UN) stake by 40.48% reported in 2017Q4 SEC filing. Fort Washington Investment Advisors Inc acquired 534,497 shares as Unilever N V (UN)’s stock declined 4.54%. The Fort Washington Investment Advisors Inc holds 1.85M shares with $104.46M value, up from 1.32 million last quarter. Unilever N V now has $160.89 billion valuation. The stock increased 0.34% or $0.195 during the last trading session, reaching $57.205. About 679,296 shares traded. Unilever N.V. (NYSE:UN) has risen 6.36% since April 16, 2017 and is uptrending. It has underperformed by 5.19% the S&P500.

Fort Washington Investment Advisors Inc decreased Vanguard Scottsdale Fds Int (VCIT) stake by 9,776 shares to 41,207 valued at $3.60 million in 2017Q4. It also reduced Eqt Midstream Partners Lp Limited Partners (NYSE:EQM) stake by 19,900 shares and now owns 99,500 shares. Schwab Charles Corp New (NYSE:SCHW) was reduced too.

Among 11 analysts covering Unilever NV (NYSE:UN), 7 have Buy rating, 1 Sell and 3 Hold. Therefore 64% are positive. Unilever NV had 13 analyst reports since September 25, 2015 according to SRatingsIntel. JP Morgan downgraded the stock to “Neutral” rating in Wednesday, December 7 report. As per Tuesday, December 13, the company rating was upgraded by Jefferies. The rating was upgraded by JP Morgan to “Overweight” on Tuesday, January 12. The firm has “Hold” rating by Liberum Capital given on Monday, March 27. The stock of Unilever N.V. (NYSE:UN) earned “Buy” rating by Argus Research on Friday, March 23. The stock of Unilever N.V. (NYSE:UN) earned “Overweight” rating by Barclays Capital on Friday, March 24. The stock of Unilever N.V. (NYSE:UN) has “Buy” rating given on Friday, September 25 by Berenberg. The firm has “Buy” rating given on Wednesday, August 31 by Citigroup. The firm has “Buy” rating given on Wednesday, March 28 by UBS. The company was downgraded on Thursday, August 10 by RBC Capital Markets.

Among 4 analysts covering Intec Pharma (NASDAQ:NTEC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intec Pharma has $15.0 highest and $9 lowest target. $10.75’s average target is 107.53% above currents $5.18 stock price. Intec Pharma had 9 analyst reports since September 11, 2015 according to SRatingsIntel. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) earned “Buy” rating by Oppenheimer on Thursday, June 22. The firm has “Buy” rating given on Thursday, August 10 by Roth Capital. The company was maintained on Thursday, August 3 by Roth Capital. Roth Capital initiated the shares of NTEC in report on Friday, September 11 with “Buy” rating. Oppenheimer maintained it with “Buy” rating and $15.0 target in Thursday, September 21 report. The rating was initiated by Maxim Group on Wednesday, September 16 with “Buy”. The rating was initiated by TH Capital with “Buy” on Friday, September 11. Roth Capital maintained it with “Buy” rating and $9.5000 target in Monday, July 24 report. Oppenheimer maintained Intec Pharma Ltd. (NASDAQ:NTEC) on Thursday, November 16 with “Buy” rating.

Analysts await Intec Pharma Ltd. (NASDAQ:NTEC) to report earnings on June, 8. After $-0.39 actual earnings per share reported by Intec Pharma Ltd. for the previous quarter, Wall Street now forecasts -33.33% EPS growth.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $173.83 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients.

Intec Pharma Ltd. (NASDAQ:NTEC) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>